Moderna announced that its vaccine for respiratory syncytial virus (RSV) for older adults was 84% effective at preventing at least two symptoms of the illness and 82% effective at preventing at least three symptoms.
Jan. 18, 2023 – Moderna's vaccine for respiratory syncytial virus for older adults was 84% effective at preventing at least two symptoms of the illness and 82% effective at preventing at least three symptoms, the company announced this week.
"It's very exciting to see progress in RSV vaccines in older adults, and I think both of those vaccines [Pfizer and GlaxoSmithKline] have shown pretty remarkable results as well," Moderna president Stephen Hoge toldThe RSV vaccine that Moderna developed is for adults ages 60 and older. The company said some of its RSV vaccine technology is shared by its COVID-19 vaccine.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna says RSV vaccine is 84% effective at preventing disease in older adultsRSV infections kill between 6,000 and 10,000 older adults every year and result in 60,000 to 120,000 hospitalizations, according to the CDC.
Read more »
Moderna says RSV vaccine 84% effective at preventing symptoms in older adultsModerna Inc said on Tuesday that its experimental messenger RNA vaccine for respiratory syncytial virus (RSV) was 83.7% effective in a late-stage trial at preventing at least two symptoms, such as cough and fever, in adults aged 60 and older.
Read more »
Moderna says its RSV vaccine for older adults is 84% effective at preventing serious illnessModerna announced Tuesday its RSV vaccine for older adults was about 84% effective at preventing severe disease and the company plans to ask the FDA for approval in 2023.
Read more »
Moderna says its RSV vaccine is 84% effective in older adultsModerna announced positive results from its late-stage RSV vaccine trial in older adults.
Read more »
Moderna’s RSV Vaccine Reduces Risk of Respiratory Diseases, Study FindsAn RSV vaccine that Moderna is developing significantly reduced the risk of respiratory diseases in a key study, the company said
Read more »
Moderna Reports RSV Vaccine Cuts Risk of Respiratory Diseases in Older AdultsAn RSV vaccine that Moderna is developing significantly reduced the risk of respiratory diseases in a key study, the company said
Read more »